Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study

NCT05524974 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT05524974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study
Lead sponsor
Fujian Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2022
Completion date
September 1, 2027
Enrollment
203 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric cancer